TPST

Tempest Therapeutics (TPST)

About Tempest Therapeutics (TPST)

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

Details

Daily high

$3.00

Daily low

$2.89

Price at open

$2.90

52 Week High

$13.65

52 Week Low

$2.87

Market cap

14.5M

Dividend yield

0.00%

Volume

58,402

Avg. volume

262,551

P/E ratio

-.29

Tempest Therapeutics News